15 Best S&P 500 Dividend Stocks to Buy in 2026

5. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 93

Dividend Yield as of January 21: 3.23%

On January 20, Berenberg raised its price target on AbbVie Inc. (NYSE:ABBV) to $275 from $270, while keeping a Buy rating on the stock. The firm said it is feeling more confident about AbbVie’s outlook, especially after lifting its forecasts for Skyrizi and Rinvoq, calling their growth trajectory “exceptional.”

In other news, on January 12, AbbVie drew attention again after news broke that the company had reached a three-year agreement with the Trump administration aimed at lowering drug prices in the US, according to Reuters. As part of the broader arrangement, AbbVie also committed to investing $100 billion over the next 10 years into US-based research and development.

AbbVie said the investment will also support manufacturing expansion and help grow its direct-to-patient platform, TrumpRx, which would offer commonly used medicines such as Alphagan, Combigan, Humira, and Synthroid through the company’s own websites. Under the deal, the company said it would receive exemptions from tariffs and future pricing mandates, though it added that the rest of the details are confidential. The agreement comes as the Trump administration has been putting pressure on drugmakers to bring down prices, pointing out that Americans often pay close to three times more for prescription drugs than people in other developed countries.

That said, the benefits of TrumpRx may not reach everyone. Most insured Americans already purchase medications through set co-pays or co-insurance, which are tied to the list price, meaning a direct-cash option may matter more for people paying out of pocket.

AbbVie Inc. (NYSE:ABBV) is a major global biopharmaceutical company, focused on developing and selling medicines across a wide range of therapeutic areas, backed by large-scale research, manufacturing, and commercialization operations.